Tamara N. Kimball

Dr. Tamara N. Kimball

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PEPei Chia Eng
Pei Chia Eng
LTLyeann Li Ying Tan
Lyeann Li Ying Tan
TKTamara N. Kimball
Tamara N. Kimball
SPSavvina Prapiadou
Savvina Prapiadou
Benjamin Yong-Qiang TanBenjamin Yong-Qiang Tan
Benjamin Yong-Qiang Tan
Ischemic stroke is a major cause of mortality and disability and has become a significant public health concern among women. Overall, women have more ischemic stroke events than men, in part due to their longer life span, and also suffer from more severe stroke-related disabilities compared to men. Women are also more likely than men to present with atypical non-focal neurological symptoms, potentially leading to delayed diagnosis and treatment. Female-specific risk factors, especially those related to pregnancy, are often under-recognized. A woman’s risk for ischemic stroke evolves throughout her lifespan, influenced by various factors including the age of menarche, pregnancy and its complications (such as parity, pre-eclampsia/eclampsia, and preterm delivery), postpartum challenges, oral contraceptive use, and menopause. Additionally, vascular risk factors like hypertension, diabetes, and atrial fibrillation are more prevalent among older women. Despite comparable treatment efficacies, women generally experience poorer outcomes after stroke. They also face higher rates of post-stroke depression, further complicating recovery. Although significant strides have been made in reducing the incidence of ischemic stroke, our understanding of the unique risks, underlying causes, and long-term consequences for women remains limited. While sex hormones may explain some differences, a lack of awareness regarding sex-related disparities can result in suboptimal care. This review aims to illuminate the unique risks and burdens of ischemic stroke faced by women, advocating for a more nuanced understanding to enhance prevention and treatment strategies.


8 July 2025 in Neurology
Verified
Journal Article
Closed access
PDF file
TKTamara N. Kimball
Tamara N. Kimball
SPSavvina Prapiadou
Savvina Prapiadou
RTReinier W.P. Tack
Reinier W.P. Tack
Benjamin Yong-Qiang TanBenjamin Yong-Qiang Tan
Benjamin Yong-Qiang Tan
JSJasper R. Senff
Jasper R. Senff
CAChristopher D. Anderson
Christopher D. Anderson
Background and ObjectivesStroke, dementia, and late-life depression (LLD) are age-related brain diseases that pose significant public health challenges and costs. Leucocyte telomere length (LTL) is...

1 April 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
RTReinier W. P. Tack
Reinier W. P. Tack
JSJasper R. Senff
Jasper R. Senff
TKTamara N. Kimball
Tamara N. Kimball
SPSavvina Prapiadou
Savvina Prapiadou
Benjamin Yong-Qiang TanBenjamin Yong-Qiang Tan
Benjamin Yong-Qiang Tan
CAChristopher D. Anderson
Christopher D. Anderson
Background: Stroke and dementia are leading causes of mortality and can be prevented through risk factor management. Risk factor assessment requires laboratory or physical measurements. We aimed to determine whether self‐reported risk factors serve as reliable proxies and predict stroke‐ and dementia‐related mortality. Methods and Results: We used cross‐sectional data from the NHANES (National Health and Nutrition Examination Survey) from 1999 to 2018 linked to National Death Index records. We included participants with available data on self‐reported and measured hypertension, hypercholesterolemia, diabetes, kidney disease, hearing impairment and overweight. Reliability was assessed using F1 scores, and used survey‐weighted Cox‐proportional hazards models evaluated associations with stroke‐ or dementia‐related mortality. Reliability of self‐reported risk factors was highest in overweight (F1 score 0.81, sensitivity 76%, specificity 77%) and diabetes (F1 score 0.71, sensitivity 77%, specificity 97%) and lowest for kidney disease (F1 score 0.25, sensitivity 16%, specificity 98%). Self‐reported hypertension (hazard ratio [HR], 1.49 [95% CI, 1.14–1.94]) and diabetes (HR, 1.58 [95% CI, 1.18–2.12]) were associated with stroke‐related mortality, comparable to measured risk factors. For dementia‐related mortality, only measured hearing impairment (all dementia cases had hearing impairment at baseline) and both self‐reported (HR, 0.50 [95% CI, 0.37–0.68]) and measured overweight (HR, 0.70 [95% CI, 0.52–0.93]) were associated. Conclusions: In conclusion, the reliability and validity of self‐reported risk factors for stroke and dementia differ between risk factors. Although self‐reported measures vary in their reliability, they perform equally as well as objective metrics for evaluating the risk of stroke‐ and dementia‐related mortality.

27 January 2026 in Neurology
Verified
Journal Article
Closed access
SPSavvina Prapiadou
Savvina Prapiadou
Benjamin Yong-Qiang TanBenjamin Yong-Qiang Tan
Benjamin Yong-Qiang Tan
TKTamara N. Kimball
Tamara N. Kimball
SMSamantha Mora
Samantha Mora
RTReinier W.P. Tack
Reinier W.P. Tack
CAChristopher D. Anderson
Christopher D. Anderson
Cerebral small vessel disease (cSVD) is a major contributor to stroke and dementia, often beginning decades before clinical symptoms appear. While MRI markers offer critical insight into cSVD burden, blood-based biomarkers may offer a more accessible complement to neuroimaging. We investigated whether plasma glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) are associated with MRI markers of cSVD in middle-aged adults and whether they are associated with longitudinal progression. We conducted a retrospective analysis of prospectively collected data from the UK Biobank cohort. Participants aged 40-60 years at baseline (2006-2010) with plasma biomarker measurements and follow-up MRI scans (2014-2019) were included. Individuals with prevalent neurologic conditions were excluded. We assessed 3 MRI markers of cSVD: white matter hyperintensities (WMHs), fractional anisotropy (FA), and mean diffusivity (MD). Three analytical approaches were used: associations between baseline biomarkers and future MRI markers, associations between baseline biomarkers and longitudinal MRI changes, and correlations between longitudinal biomarker and MRI changes. Robust regression models were adjusted for age, sex, and cerebrovascular risk factors. Among 5,270 participants (mean age 54.2 ± 7.8 years; 53.4% female), higher baseline GFAP levels were significantly associated with all 3 MRI cSVD markers-WMH volume (β = 0.06, 95% CI 0.01-0.10, p = 0.014), FA (β = 0.08, 95% CI 0.03-0.13, p = 0.001), and MD (β = 0.14, 95% CI 0.09-0.18, p < 0.001)-after a follow-up of 9 years. Among 1,317 participants with longitudinal MRI data, baseline GFAP was associated with progression of FA (β = 0.012, 95% CI 0.001-0.023, p = 0.033) and MD (β = 0.020, 95% CI 0.003-0.038, p = 0.025) over 3 years. NfL was not significantly associated with any MRI cSVD marker. Longitudinal changes in both biomarkers showed no significant associations with concurrent MRI progression. Plasma GFAP levels were associated with subsequent changes in white matter integrity among middle-aged adults, suggesting potential utility as an early indicator of cSVD vulnerability. These associations, observed nearly a decade after biomarker measurement, highlight GFAP's potential for long-term risk stratification. Blood-based biomarkers may support earlier identification of individuals at heightened risk of cSVD, enabling preventive strategies when interventions may be most effective.

1 April 2025 in Stroke
Verified
Journal Article
Closed access
RTReinier W.P. Tack
Reinier W.P. Tack
Benjamin Yong-Qiang TanBenjamin Yong-Qiang Tan
Benjamin Yong-Qiang Tan
JSJasper R. Senff
Jasper R. Senff
SPSavvina Prapiadou
Savvina Prapiadou
TKTamara N. Kimball
Tamara N. Kimball
CAChristopher D. Anderson
Christopher D. Anderson
BACKGROUND: Because treatment with anticoagulants can prevent recurrent strokes, identification of patients at risk for incident atrial fibrillation (AF) after stroke is crucial. We aimed to investigate whether the addition of AF polygenic risk scores (PRSs) to existing clinical risk predictors could improve prediction of AF after stroke. METHODS: Patients diagnosed with ischemic stroke at the Massachusetts General Hospital between 2003 and 2017 were included. Clinical AF risk was estimated using the Recalibrated Cohorts for Heart and Aging Research in Genomic Epidemiology Atrial Fibrillation model, and genetic risk was estimated using a contemporary AF PRS from 1 093 050 variants. Patients were divided into clinical and genetic risk tertiles. Cox proportional hazards models at different follow-up windows were fit, and C indices and percentile-based net reclassification index were used to determine the improvement of clinical risk models with the addition of AF PRS. RESULTS: Of 1004 stroke survivors, 900 (90%) were non-Hispanic White, 413 (41%) were female, and the mean age was 67 (SD, 14) years. Of 1004 survivors, 239 (23.8%) had prevalent AF and 87 of 765 (11.4%) remaining patients developed incident AF during 5 years of follow-up. AF PRS was associated with greater risk of incident AF after stroke (hazard ratio, 1.21 [95% CI, 0.97–1.50] per 1-SD increase), although the association was not statistically significant. PRS improved discrimination in the first month (area under the curve, 0.78 [95% CI, 0.70–0.82] versus 0.71 [95% CI, 0.60–0.82]; P =0.05), with more modest estimates across longer time windows. CONCLUSIONS: Addition of an AF PRS to clinical risk models may improve identification of individuals at risk of AF after stroke, particularly within the first month.